rilpivirine


Also found in: Dictionary, Wikipedia.

rilpivirine

(ril-pi-vir-een ) ,

Edurant

(trade name)

Classification

Therapeutic: antiretrovirals
Pharmacologic: non nucleoside reverse transcriptase inhibitors
Pregnancy Category: B

Indications

Treatment-naïve adult patients with HIV infection with HIV-1 RNA ≤100,000 copies/mL at start of therapy.

Action

Inhibits HIV-replication by non-competitively inhibiting HIV reverse transcriptase.

Therapeutic effects

Slowed progression of HIV infection and decreased occurrence of sequelae. Increases CD4 cell counts and decreases viral load.

Pharmacokinetics

Absorption: Well absorbed following oral administration.
Distribution: Unknown.
Protein Binding: 99.7%.
Metabolism and Excretion: Mostly metabolized by the liver (CYP3A enzyme system); 25% excreted in feces unchanged, <1% excreted unchanged in urine.
Half-life: 50 hr.

Time/action profile (blood levels)

ROUTEONSETPEAKDURATION
POunknown4–5 hr24 hr

Contraindications/Precautions

Contraindicated in: Concurrent use of drugs that inhibit the CYP3A enzyme system or ↑ gastric pH (↓ blood levels and effectiveness, ↑ resistance); Lactation: Breast feeding should be avoided due to possible transmission of virus in breast milk.
Use Cautiously in: Concurrent use of drugs that ↑ risk of torsades de pointes (may ↑ risk of arrhythmias);History of depression or suicide attempt;Hepatitis B or CConcurrent use of antacids or H2 antagonists (↓ blood levels and effectiveness); Geriatric: Consider ↓ hepatic/renal/cardiac function, concurrent diseases, and drug therapy; Obstetric: Use only if potential maternal benefit justifies potential risk to fetus; Pediatric: Safety and effectiveness not established.

Adverse Reactions/Side Effects

Central nervous system

  • depression
  • dizziness
  • headache
  • insomnia

Dermatologic

  • rash

Gastrointestinal

  • hepatotoxicity

Miscellaneous

  • fat redistribution
  • immune reconstitution syndrome

Interactions

Drug-Drug interaction

Drugs that inhibit the CYP3A enzyme system including carbamazepine, dexamethasone (more than a single dose), oxcarbazepine, phenobarbital, phenytoin, rifabutin, rifampin, or, rifapentine ↓ blood levels and effectiveness and promote of virologic resistance; concurrent use contraindicated.Proton pump inhibitors including esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole ↓ blood levels and effectiveness and may ↑ resistance; concurrent use contraindicated.Concurrent use with antacids may ↓ blood levels and effectiveness; use with caution, administer 2 hr before or 4 hr after.Concurrent use with H2 antagonists may ↓ blood levels and effectiveness; use with caution, administer 12 hr before or 4 hr after.Blood levels may be ↑ by clarithromyin, erythromycin, or troleandomycin ; consider azithromycin.Concurrent use with drugs that ↑ risk of torsades de pointes may ↑ risk of serious arrhythmias.Concurrent use of other non-nucleoside reverse transcriptase inhibitors may alter blood levels and should be avoided.May alter blood levels of methadone ; monitor clinical effects.Concurrent use of St. John's wort ↓ blood levels and effectiveness, ↑ resistance; concurrent use contraindicated.

Route/Dosage

Oral (Adults) 25 mg once daily.

Availability

Tablets: 25 mg
In combination with: emtricitabine and tenofovir (Complera). See combination drugs.

Nursing implications

Nursing assessment

  • Assess for change in severity of HIV symptoms and for symptoms of opportunistic infections during therapy.
  • Monitor closely for notable changes in behavior that could indicate the emergence or worsening of suicidal thoughts or behavior or depression.
  • Lab Test Considerations: Monitor viral load and CD4 cell count regularly during therapy.
    • Monitor liver function tests before and periodically during therapy in patients with underlying liver disease, hepatitis B or C, or marked ↑ transaminase. May cause ↑ serum creatinine, AST, ALT, total bilirubin, total cholesterol, LDL, and triglycerides.

Potential Nursing Diagnoses

Risk for infection (Indications)
Noncompliance (Patient/Family Teaching)

Implementation

  • Oral: Administer once daily with a meal.

Patient/Family Teaching

  • Emphasize the importance of taking rilpivirine as directed, at the same time each day. It must always be used in combination with other antiretroviral drugs. Do not take more than prescribed amount and do not stop taking without consulting health care professional. Take missed doses with a meal if remembered <12 hr of the time it is usually taken, then return to regular schedule. If more than 12 hr from time dose is usually taken, omit dose and resume dosing schedule; do not double doses. Advise patient to read Patient Information prior to starting therapy and with each Rx refill in case of changes.
  • Advise patient to take antacids 2 hr before or 4 hr after and H2 antagonists 12 hr before or 4 hr after rilpivirine.
  • Instruct patient that rilpivirine should not be shared with others.
  • Inform patient that rilpivirine does not cure AIDS or prevent associated or opportunistic infections. Rilpivirine does not reduce the risk of transmission of HIV to others through sexual contact or blood contamination. Caution patient to use a condom and to avoid sharing needles or donating blood to prevent spreading the AIDS virus to others. Advise patient that the long-term effects of rilpivirine are unknown at this time.
  • Inform patients and families of risk of suicidal thoughts and behavior and advise that behavioral changes, emergency or worsening signs and symptoms of depression, unusual changes in mood, or emergence of suicidal thoughts, behavior, or thoughts of self-harm should be reported to health care professional immediately.
  • Immune reconstitution syndrome may trigger opportunistic infections or autoimmune disorders. Notify health care professional if symptoms occur.
  • May cause dizziness. Caution patient to avoid driving or other activities requiring alertness until response to medication is known.
  • Advise patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care professional before taking other medications, especially St. John's wort.
  • Inform patient that changes in body fat (increased fat in upper back and neck, breast, and around back, chest, and stomach area; loss of fats from legs, arms, and face) may occur.
  • Advise patients to notify health care professional if pregnancy is planned or suspected. Advise patient to avoid breast feeding during rilpivirine therapy.
  • Emphasize the importance of regular follow-up exams and blood counts to determine progress and monitor for side effects.

Evaluation/Desired Outcomes

  • Delayed progression of AIDS and decreased opportunistic infections in patients with HIV.
  • Decrease in viral load and increase in CD4 cell counts.
References in periodicals archive ?
Following the results of the proof of concept two-drug oral dose-ranging study LATTE, LATTE 2 was initiated as a phase IIb, multicentre, open label 96 week study investigating the safety and efficacy of this first all-injectable long acting combination regimen of rilpivirine and cabotegravir to maintain suppression of viral load.
Patients in every group developed prolongations in QTc interval, though less so with the 25-mg/day dose of rilpivirine.
Rilpivirine (Tibotec) is an NNRTI and a di-aryl-pyrimidine (DAPY).
Once the drug-containing nanoparticles are injected, they are slowly broken down and gradually release their rilpivirine payload.
A phase III study is ongoing as part of a collaboration with Janssen, to investigate dolutegravir in combination with rilpivirine, as a potential maintenance therapy for adult patients with HIV who have already achieved viral suppression with a three drug regimen.
Viral suppression rates (plasma HIV-1 RNA <50 c/ml by FDA snapshot analysis) for patients at 32 weeks receiving two drug maintenance therapy with investigational long acting cabotegravir (CAB LA) and long acting rilpivirine (RPV LA) dosed every 8 weeks (Q8W, 95%) or every 4 weeks (Q4W, 94%) were comparable to the rate observed in patients continuing with a three drug oral regimen of investigational CAB + NRTIs (91%).
24) Prescribing information for rilpivirine, the newest nonnucleoside, does not mention insulin resistance, glucose, or diabetes.
Complera combines Gilead's Truvada([R]) (emtricitabine and tenofovir disoproxil fumarate) with Janssen R&D Ireland's rilpivirine (marketed as Edurant([R])).
If approved by the European Commission, rilpivirine will become available for the first time for the treatment of adolescents with HIV-1, ages 12 to <18 years.
Lot No 15 - emtricitabine / Rilpivirine / tenofovir disoproxil | 200/25 / 245mg | Tablet | 30 - Number of packages 1000
7) Those drugs include the booster cobicistat (a constituent of Stribild), the integrase inhibitor dolutegravir, and the nonnucleoside rilpivirine.
24-week data from a Phase 3 clinical trial, SPIRIT(Switching boosted PI to Rilpivirine In Combination with Truvada as a Single Tablet Regimen), which evaluated virologically suppressed treatment-experienced HIV patients switching from a multi-pill regimen containing a ritonavir-boosted protease inhibitor to the once-daily single tablet regimen Complera.